Company intelligence / Profile preview

ToolGen

Seoul, Seoul, South Korea

Ownership: Private
Employees: ~80
Development stage: Other

Overview

ToolGen is a leading South Korean biotech company developing CRISPR, ZFN, and TALEN gene editing technologies, with an extensive IP portfolio, broad application in biomedicine and agriculture, and active licensing of core patents; current clinical results are predominantly pre-clinical, with research publications cited in areas such as Charcot-Marie-Tooth disease and experimental CAR-T approaches

Therapeutic areas: OtherRare Diseases
Modalities: CRISPR-based therapyGene therapyGenome editing technology
Industry: Biotech

Drug pipeline

3 assets

EGFR-TALEN

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Life Technologies (now Thermo Fisher Scientific)Thermo Fisher ScientificBayer (Monsanto, for agriculture IP licensing)KeyGene

Beyond the preview

Go deeper on ToolGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ToolGen.

Explore the full profile